Gilead Sciences (NASDAQ: GILD) reported Q1 EPS of $1.37, $0.16 worse than the analyst estimate of $1.53. Revenue for the quarter came in at $6.4 billion versus the consensus estimate of $6.31 billion.

GUIDANCE:

Gilead Sciences sees FY2023 EPS of $6.60-$7.00, versus the consensus of $6.84. Gilead Sciences sees FY2023 revenue of $26-26.5 billion, versus the consensus of $26.73 billion.

For earnings history and earnings-related data on Gilead Sciences (GILD) click here.